Astaxanthin and omega-3 fatty acids individually and in combination protect against oxidative stress via the Nrf2-ARE pathway

Food and Chemical Toxicology

Volumn 62, Issue , 2013, Pages 869-875

  Saw, Constance Lay Lay ^a   Yang, Anne Yuqing ^a,b   Guo, Yue ^a,b   Kong, Ah Ng Tony ^a  

^a RUTGERS UNIVERSITY   (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antioxidant response element; Astaxanthin; Docosahexaenoic acid; Eicosapentaenoic acid; Nuclear factor (erythroid derived 2) like 2; Oxidative stress

Indexed keywords

ASTAXANTHIN; DOCOSAHEXAENOIC ACID; GLUTATHIONE; ICOSAPENTAENOIC ACID; MESSENGER RNA; OMEGA 3 FATTY ACID; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GSTM2; TRANSCRIPTION FACTOR HO 1; TRANSCRIPTION FACTOR NQO1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

2,2-DIPHENYL-1-PICRYLHYDRAZYL; ANTIOXIDANT RESPONSE ELEMENT; ARE; AST; ASTAXANTHIN; CI; COMBINATION INDEX; DHA; DIMETHYL SULFOXIDE; DMSO; DOCOSAHEXAENOIC ACID; DPPH; EICOSAPENTAENOIC ACID; EPA; FBS; FETAL BOVINE SERUM; GLUTATHIONE; GLUTATHIONE S-TRANSFERASE M2; GSH; GSTM2; HEME OXYGENASE-1; HO-1; NAD(P)H: QUINONE OXYDOREDUCTASE 1; NQO1; NRF2; NUCLEAR FACTOR (ERYTHROID-DERIVED 2)-LIKE 2; OD; OPTICAL DENSITY; OXIDATIVE STRESS; POLYUNSATURATED FATTY ACIDS; PUFAS; QRT-PCR; QUANTITATIVE REVERSE-TRANSCRIPTASE POLYMERASE CHAIN REACTION; RADICAL SCAVENGING ACTIVITY; RSA; SFN; SULFORAPHANE;

ANTIOXIDANT RESPONSE ELEMENTS; ANTIOXIDANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FATTY ACIDS, OMEGA-3; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HEME OXYGENASE-1; HEP G2 CELLS; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; XANTHOPHYLLS;

EID: 84887533496     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.10.023     Document Type: Article

References (43)

1. Adkins Y., Kelley D.S. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J. Nutr. Biochem. 2010, 21:781-792.
2. Aoi W., Naito Y., Sakuma K., Kuchide M., Tokuda H., Maoka T., Toyokuni S., Oka S., Yasuhara M., Yoshikawa T. Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Antioxid. Redox Signal 2003, 5:139-144.
3. Aruoma O.I. Methodological considerations for characterizing potential antioxidant actions of bioactive components in plant foods. Mutat. Res. 2003, 523-524:9-20.
4. Barros M.P., Marin D.P., Bolin A.P., de Cassia Santos Macedo P., Campoio T.R., Fineto C., Guerra B.A., Polotow T.G., Vardaris C., Mattei R., Otton R. Combined astaxanthin and fish oil supplementation improves glutathione-based redox balance in rat plasma and neutrophils. Chem. Biol. Interact. 2012, 197:58-67.
5. Calder P.C. N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 2006, 83:1505S-1519S.
6. Chan L.W., Cheah E.L., Saw C.L., Weng W., Heng P.W. Antimicrobial and antioxidant activities of Cortex Magnoliae Officinalis and some other medicinal plants commonly used in South-East Asia. Chin. Med. 2008, 3:15.
7. Chen C., Yu R., Owuor E.D., Kong A.N. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch. Pharm. Res. 2000, 23:605-612.
8. Choi H.D., Kim J.H., Chang M.J., Kyu-Youn Y., Shin W.G. Effects of astaxanthin on oxidative stress in overweight and obese adults. Phytother. Res. 2011, 25:1813-1818.
9. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
10. Finocchiaro C., Segre O., Fadda M., Monge T., Scigliano M., Schena M., Tinivella M., Tiozzo E., Catalano M.G., Pugliese M., Fortunati N., Aragno M., Muzio G., Maggiora M., Oraldi M., Canuto R.A. Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br. J. Nutr. 2012, 108:327-333.
11. Hu R., Saw C.L., Yu R., Kong A.N. Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory. Antioxid. Redox Signal 2010, 13:1679-1698.
12. Iwamoto T., Hosoda K., Hirano R., Kurata H., Matsumoto A., Miki W., Kamiyama M., Itakura H., Yamamoto S., Kondo K. Inhibition of low-density lipoprotein oxidation by astaxanthin. J. Atheroscler. Thromb. 2000, 7:216-222.
13. Jyonouchi H., Sun S., Iijima K., Gross M.D. Antitumor activity of astaxanthin and its mode of action. Nutr. Cancer 2000, 36:59-65.
14. Kagan M.L., West A.L., Zante C., Calder P.C. Acute appearance of fatty acids in human plasma - a comparative study between polar-lipid rich oil from the microalgae nannochloropsis oculata and krill oil in healthy young males. Lipids Health Dis. 2013, 12:102.
15. Kang J.O., Kim S.J., Kim H. Effect of astaxanthin on the hepatotoxicity, lipid peroxidation and antioxidative enzymes in the liver of CCl4-treated rats. Methods Find Exp. Clin. Pharmacol. 2001, 23:79-84.
16. Khor T.O., Yu S., Kong A.N. Dietary cancer chemopreventive agents - targeting inflammation and Nrf2 signaling pathway. Planta Med. 2008, 74:1540-1547.
17. Kim B.R., Hu R., Keum Y.S., Hebbar V., Shen G., Nair S.S., Kong A.N. Effects of glutathione on antioxidant response element-mediated gene expression and apoptosis elicited by sulforaphane. Cancer Res. 2003, 63:7520-7525.
18. Kobayashi M. In vivo antioxidant role of astaxanthin under oxidative stress in the green alga Haematococcus pluvialis. Appl. Microbiol. Biotechnol. 2000, 54:550-555.
19. Lee D.H., Kim C.S., Lee Y.J. Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem. Toxicol. 2011, 49:271-280.
20. Lee J.J., Kong M., Ayers G.D., Lotan R. Interaction index and different methods for determining drug interaction in combination therapy. J. Biopharm. Stat. 2007, 17:461-480.
21. Leite M.F., Lima A.M., Otton R. Combination of astaxanthin and fish oil supplementation alters antioxidant enzyme profile of dental pulp tissue. Int. Endod. J. 2012, 45:1109-1115.
22. Maeda H., Hosokawa M., Sashima T., Miyashita K. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J. Agric. Food Chem. 2007, 55:7701-7706.
23. Manerba A., Vizzardi E., Metra M., Dei Cas L. N-3 PUFAs and cardiovascular disease prevention. Future Cardiol. 2010, 6:343-350.
24. Nagendraprabhu P., Sudhandiran G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Invest New Drugs 2011, 29:207-224.
25. Ohgami K., Shiratori K., Kotake S., Nishida T., Mizuki N., Yazawa K., Ohno S. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol. Vis. Sci. 2003, 44:2694-2701.
26. Otton R., Marin D.P., Bolin A.P., de Cassia Santos Macedo R., Campoio T.R., Fineto C., Guerra B.A., Leite J.R., Barros M.P., Mattei R. Combined fish oil and astaxanthin supplementation modulates rat lymphocyte function. Eur. J. Nutr. 2012, 51:707-718.
27. Peng J., Yuan J.P., Wang J.H. Effect of diets supplemented with different sources of astaxanthin on the gonad of the sea urchin Anthocidaris crassispina. Nutrients 2012, 4:922-934.
28. Rusca A., Di Stefano A.F., Doig M.V., Scarsi C., Perucca E. Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers. Eur. J. Clin. Pharmacol. 2009, 65:503-510.
29. Saw C.L., Cintron M., Wu T.Y., Guo Y., Huang Y., Jeong W.S., Kong A.N. Pharmacodynamics of dietary phytochemical indoles I3C and DIM: induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm. Drug Dispos. 2011, 32:289-300.
30. Saw C.L., Huang Y., Kong A.N. Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem. Pharmacol. 2010, 79:421-430.
31. Saw C.L., Kong A.N. Nuclear factor-erythroid 2-related factor 2 as a chemopreventive target in colorectal cancer. Expert Opin. Ther. Targets 2011, 15:281-295.
32. Shen G., Kong A.N. Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm. Drug Dispos. 2009, 30:345-355.
33. Silva Jde A., Trindade E.B., Fabre M.E., Menegotto V.M., Gevaerd S., Buss Zda S., Frode T.S. Fish oil supplement alters markers of inflammatory and nutritional status in colorectal cancer patients. Nutr. Cancer 2012, 64:267-273.
34. Slocum S.L., Kensler T.W. Nrf2: control of sensitivity to carcinogens. Arch. Toxicol. 2011, 85:273-284.
35. Talalay P., Fahey J.W., Holtzclaw W.D., Prestera T., Zhang Y. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol. Lett. 1995, 82-83:173-179.
36. Tripathi D.N., Jena G.B. Astaxanthin intervention ameliorates cyclophosphamide-induced oxidative stress, DNA damage and early hepatocarcinogenesis in rat: role of Nrf2, p53, p38 and phase-II enzymes. Mutat. Res. 2010, 696:69-80.
37. Uchiyama K., Naito Y., Hasegawa G., Nakamura N., Takahashi J., Yoshikawa T. Astaxanthin protects beta-cells against glucose toxicity in diabetic db/db mice. Redox Rep. 2002, 7:290-293.
38. Wang H., Khor T.O., Saw C.L., Lin W., Wu T., Huang Y., Kong A.N. Role of Nrf2 in suppressing LPS-induced inflammation in mouse peritoneal macrophages by polyunsaturated fatty acids docosahexaenoic acid and eicosapentaenoic acid. Mol. Pharm. 2010, 7:2185-2193.
39. Yasui Y., Hosokawa M., Mikami N., Miyashita K., Tanaka T. Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chem. Biol. Interact 2011, 193:79-87.
40. Yu R., Lei W., Mandlekar S., Weber M.J., Der C.J., Wu J., Kong A.N. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J. Biol. Chem. 1999, 274:27545-27552.
41. Yu R., Mandlekar S., Lei W., Fahl W.E., Tan T.H., Kong A.N. P38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J. Biol. Chem. 2000, 275:2322-2327.
42. Yuan J.P., Peng J., Yin K., Wang J.H. Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae. Mol. Nutr. Food Res. 2011, 55:150-165.
43. Zhang X., Zhao W.E., Hu L., Zhao L., Huang J. Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARgamma) in K562 cancer cells. Arch. Biochem. Biophys. 2011, 512:96-106.